Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Feasibility and Safety of Personalized Autologous CD8+ T Cell Therapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies

NCT02757391 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02757391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02757391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Feasibility and Safety of Personalized Autologous CD8+ T Cell Therapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
August 9, 2019
Completion date
October 2, 2020
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, metastatic cholangiocarcinoma, metastatic colorectal carcinoma, metastatic digestive system carcinoma, metastatic esophageal carcinoma, metastatic gastric carcinoma, metastatic pancreatic adenocarcinoma, stage iv colorectal cancer ajcc v7, stage iv esophageal cancer ajcc v7, stage iv gastric cancer ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, stage iva colorectal cancer ajcc v7, stage ivb colorectal cancer ajcc v7